FDA Inspection 1277120 — Mark J. Hamblin, MD
The FDA completed an inspection of Mark J. Hamblin, MD on Jul 18, 2025 in Kansas City, KS. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 18, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Kansas City, KS (United States)
Additional Details
Clinical Investigator (CI)